SYDNEY and WESTMINSTER, Colo., June 20, 2013 /PRNewswire/ -- Sirtex Medical
Limited (ASX: SRX) and US-based Surefire Medical today announced a
sales and marketing partnership to distribute Surefire's range of
innovative infusion systems and specialty catheters for the
interventional radiology and oncology markets.
The agreement will see Sirtex exclusively distribute the
Surefire Medical range of products in the company's rapidly growing
Asia Pacific markets including
Australia.
Sirtex reported a 30 per cent growth in dose sales of its
targeted radiation treatment for liver cancer in the Asia Pacific region at the end of the third
quarter ended 31 March 2013.
Rapidly growing Surefire Medical has received regulatory
approval in the U.S., Europe,
Canada and New Zealand. Its
first-in-class infusion systems are used by numerous top-ranked
cancer centers and hospitals in these markets.
The Surefire Infusion System has been designed to enhance the
accuracy and delivery of drugs directly to tumors. Surefire
products use a patented microcatheter with an expandable tip. When
deployed, the tip dynamically responds to flow conditions to enable
more of the embolic agent to reach the intended destination while
reducing non-target delivery compared to traditional infusion
systems.
The ability to more safely and efficiently deliver embolic
agents directly to target tumors marks a significant advance in
radiation oncology procedures and in the treatment of liver
cancer.
Sirtex Medical Asia Pacific Chief Executive Officer Dr.
Burwood Chew said, "Sirtex is
constantly looking for new ways to help our customers improve the
outcomes of their patients with liver cancer. We believe this
distribution partnership will allow us to provide interventional
radiologists and oncologists with a wider range of options that may
potentially lead to improved patient outcomes, which is our shared
goal."
Surefire Medical CEO Jim Chomas
said, "A growing body of positive clinical evidence and the
enthusiasm of our increasing user base at hospitals worldwide
continue to prove the efficacy of the Surefire line of infusion
systems. The agreement with Sirtex enables our companies to
jointly pursue more effective treatment for the rising worldwide
incidence of liver cancer."
For further information please refer to www.surefiremedical.com
and sirtex.com
SIR-Spheres® is a registered trademark of Sirtex
SIR-Spheres Pty Ltd.
SOURCE Surefire Medical, Inc.